Plasmafiltration as an effective method in the removal of circulating pegylated liposomal doxorubicin (PLD) and the reduction of mucocutaneous toxicity during the treatment of advanced platinum-resistant ovarian cancer.
Adult
Aged
Antibiotics, Antineoplastic
/ adverse effects
Doxorubicin
/ adverse effects
Drug-Related Side Effects and Adverse Reactions
/ drug therapy
Female
Humans
Middle Aged
Organoplatinum Compounds
/ therapeutic use
Ovarian Neoplasms
/ drug therapy
Polyethylene Glycols
/ adverse effects
Prospective Studies
Cancer therapy
EPR effect
Hand–foot syndrome
Mucocutaneous toxicity
Ovarian cancer
Pegylated liposomal doxorubicin (PLD)
Plasmapheresis
Population kinetics
Journal
Cancer chemotherapy and pharmacology
ISSN: 1432-0843
Titre abrégé: Cancer Chemother Pharmacol
Pays: Germany
ID NLM: 7806519
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
13
06
2019
accepted:
05
10
2019
pubmed:
16
11
2019
medline:
14
8
2020
entrez:
16
11
2019
Statut:
ppublish
Résumé
The present study evaluates the safety and efficacy of double-plasma filtration (PF) to remove the exceeding pegylated liposomal doxorubicin (PLD) in circulation, thus reducing mucocutaneous toxicity. A total of 16 patients with platinum-resistant ovarian cancer were treated with 50 mg/m The patients received a median of 3 (2-6) chemotherapy cycles. A total of 53 cycles with PF were evaluated, which removed 31% (10) of the dose; on the other hand, the fraction eliminated prior to PF was of 34% (7). Exposure to NLD reached only 10% of exposure to the parent PLD. PLD-related toxicity was low, finding only one case of grade 3 hand-foot syndrome (6.7%) and grade 1 mucositis (6.7%). Other adverse effects were also mild (grade 1-2). PF-related adverse effects were low (7%). Median progression-free survival (PFS) and overall survival (OS) was of 3.6 (1.5-8.1) and 7.5 (1.7-26.7) months, respectively. Furthermore, 33% of the patients achieved stable disease (SD), whereas that 67% progressed. PF can be considered as safe and effective for the extracorporeal removal of PLD, resulting in a lower incidence of mucocutaneous toxicity.
Identifiants
pubmed: 31728628
doi: 10.1007/s00280-019-03976-2
pii: 10.1007/s00280-019-03976-2
doi:
Substances chimiques
Antibiotics, Antineoplastic
0
Organoplatinum Compounds
0
liposomal doxorubicin
0
Polyethylene Glycols
3WJQ0SDW1A
Doxorubicin
80168379AG
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
353-365Références
EMA (2014) Summary of product characteristics Caelyx (EPAR). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000089/WC500020180.pdf . Accessed 27 Dec 2015
Gabizon AA, Patil Y, La-Beck NM (2016) New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy. Drug Resist Update 29:90–106. https://doi.org/10.1016/j.drup.2016.10.003
doi: 10.1016/j.drup.2016.10.003
Gabizon AA (2001) Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Investig 19(4):424–436
doi: 10.1081/CNV-100103136
Gabizon A, Shmeeda H, Barenholz Y (2003) Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 42(5):419–436. https://doi.org/10.2165/00003088-200342050-00002
doi: 10.2165/00003088-200342050-00002
pubmed: 12739982
Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65(1–2):271–284
doi: 10.1016/S0168-3659(99)00248-5
Fang J, Nakamura H, Maeda H (2011) The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63(3):136–151. https://doi.org/10.1016/j.addr.2010.04.009
doi: 10.1016/j.addr.2010.04.009
pubmed: 20441782
Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC (2014) Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 66:2–25. https://doi.org/10.1016/j.addr.2013.11.009
doi: 10.1016/j.addr.2013.11.009
pubmed: 24270007
Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, Henderson R, Berry G, Gabizon A (2000) Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m
doi: 10.1023/A:1008365716693
Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, Brufman G, Gabizon A (2000) Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89(5):1037–1047
doi: 10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z
Boers-Sonderen MJ, van Herpen CM, van der Graaf WT, Desar IM, van der Logt MG, de Beer YM, Ottevanger PB, van Erp NP (2014) Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx(R)). Cancer Chemother Pharmacol 74(3):457–463. https://doi.org/10.1007/s00280-014-2514-9
doi: 10.1007/s00280-014-2514-9
pubmed: 24965180
Mayer LD, Tai LC, Ko DS, Masin D, Ginsberg RS, Cullis PR, Bally MB (1989) Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 49(21):5922–5930
pubmed: 2790807
Gabizon A, Goren D, Horowitz AT, Tzemach D, Lossos A, Siegal T (1997) Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv Drug Deliv Rev 24(2):337–344. https://doi.org/10.1016/S0169-409X(96)00476-0
doi: 10.1016/S0169-409X(96)00476-0
Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH (1998) Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 16(7):2445–2451
doi: 10.1200/JCO.1998.16.7.2445
Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G (2007) Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (‘hand-foot’ syndrome). Ann Oncol 18(7):1159–1164. https://doi.org/10.1093/annonc/mdl477
doi: 10.1093/annonc/mdl477
pubmed: 17229768
Eckes J, Schmah O, Siebers JW, Groh U, Zschiedrich S, Rautenberg B, Hasenburg A, Jansen M, Hug MJ, Winkler K, Putz G (2011) Kinetic targeting of pegylated liposomal doxorubicin: a new approach to reduce toxicity during chemotherapy (CARL-trial). BMC Cancer 11:337. https://doi.org/10.1186/1471-2407-11-337
doi: 10.1186/1471-2407-11-337
pubmed: 21816044
pmcid: 3175222
Ngoune R, Contini C, Hoffmann MM, von Elverfeldt D, Winkler K, Putz G (2018) Optimizing antitumor efficacy and adverse effects of pegylated liposomal doxorubicin by scheduled plasmapheresis: impact of timing and dosing. Curr Drug Deliv 15(9):1261–1270. https://doi.org/10.2174/1567201815666180518125839
doi: 10.2174/1567201815666180518125839
pubmed: 29779479
pmcid: 6327121
Martinkova J, Blaha M, Kubecek O, Malakova J, Spacek J, Bezouska J, Krulichova IS, Filip S (2015) Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression. Cancer Chemother Pharmacol. https://doi.org/10.1007/s00280-015-2936-z
doi: 10.1007/s00280-015-2936-z
pubmed: 26678853
Blaha M, Martinkova J, Lanska M, Filip S, Malakova J, Kubecek O, Bezouska J, Spacek J (2017) Plasma filtration for the controlled removal of liposomal therapeutics—From the apheretic site of view. Atheroscler Suppl 30:286–293. https://doi.org/10.1016/j.atherosclerosissup.2017.05.022
doi: 10.1016/j.atherosclerosissup.2017.05.022
pubmed: 29096853
Robert J (1980) Extraction of anthracyclines from biological fluids for HPLC evaluation. J Liq Chromatogr 3(10):1561–1572. https://doi.org/10.1080/01483918008062796
doi: 10.1080/01483918008062796
Bellott R, Pouna P, Robert J (2001) Separation and determination of liposomal and non-liposomal daunorubicin from the plasma of patients treated with Daunoxome. J Chromatogr B Biomed Sci Appl 757(2):257–267
doi: 10.1016/S0378-4347(01)00151-7
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG, European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92(3):205–216
doi: 10.1093/jnci/92.3.205
Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG, Stewart JS (2001) Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 7(2):243–254
pubmed: 11234875
Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A, Barenholz Y (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene–glycol coated liposomes. Cancer Res 54(4):987–992
pubmed: 8313389
Hong R-L, Tseng Y-L (2001) Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors. Cancer 91(9):1826–1833. https://doi.org/10.1002/1097-0142(20010501)91:9%3c1826:AID-CNCR24%3e3.0.CO;2-J
doi: 10.1002/1097-0142(20010501)91:9<1826::AID-CNCR24>3.0.CO;2-J
pubmed: 11335910
La-Beck NM, Zamboni BA, Gabizon A, Schmeeda H, Amantea M, Gehrig PA, Zamboni WC (2012) Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer Chemother Pharmacol 69(1):43–50. https://doi.org/10.1007/s00280-011-1664-2
doi: 10.1007/s00280-011-1664-2
pubmed: 21590446
Bally MB, Masin D, Nayar R, Cullis PR, Mayer LD (1994) Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice. Cancer Chemother Pharmacol 34(2):137–146
doi: 10.1007/BF00685931
Norda R, Stegmayr BG (2003) Therapeutic apheresis in Sweden: update of epidemiology and adverse events. Transfus Apher Sci 29(2):159–166. https://doi.org/10.1016/s1473-0502(03)00121-6
doi: 10.1016/s1473-0502(03)00121-6
pubmed: 12941356
Blaha M, Cermanova M, Blaha V, Blazek M, Maly J, Siroky O, Solichova D, Filip S, Rehacek V (2007) Safety and tolerability of long lasting LDL-apheresis in familial hyperlipoproteinemia. Ther Apher Dial 11(1):9–15. https://doi.org/10.1111/j.1744-9987.2007.00450.x
doi: 10.1111/j.1744-9987.2007.00450.x
pubmed: 17309569
Blaha M, Ptak J, Cap J, Ceeova V, Masin V, Filip S, Blazek M (2009) WAA apheresis registry in the Czech Republic: two centers experience. Transfus Apher Sci 41(1):27–31. https://doi.org/10.1016/j.transci.2009.05.005
doi: 10.1016/j.transci.2009.05.005
pubmed: 19524488
Lánská M (2018) Rheopheresis. Clinical importance of rheological, technical and further hemapheretic indicators of effectivity, side-effects and economy. Doctoral thesis
Klingel R, Fassbender C, Heibges A, Koch F, Nasemann J, Engelmann K, Carl T, Meinke M, Erdtracht B (2010) RheoNet registry analysis of rheopheresis for microcirculatory disorders with a focus on age-related macular degeneration. Ther Apher Dial 14(3):276–286. https://doi.org/10.1111/j.1744-9987.2010.00807.x
doi: 10.1111/j.1744-9987.2010.00807.x
pubmed: 20609179
Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH (2016) Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the seventh special issue. J Clin Apher 31(3):149–162. https://doi.org/10.1002/jca.21470
doi: 10.1002/jca.21470
pubmed: 27322218
pmcid: 27322218
Allen TM, Newman MS, Woodle MC, Mayhew E, Uster PS (1995) Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. Int J Cancer 62(2):199–204
doi: 10.1002/ijc.2910620215
Amantea MA, Forrest A, Northfelt DW, Mamelok R (1997) Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi’s sarcoma. Clin Pharmacol Ther 61(3):301–311. https://doi.org/10.1016/s0009-9236(97)90162-4
doi: 10.1016/s0009-9236(97)90162-4
pubmed: 9084455
Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ (1997) Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15(3):987–993. https://doi.org/10.1200/jco.1997.15.3.987
doi: 10.1200/jco.1997.15.3.987
pubmed: 9060537
Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, Rosales R, Sharpington T (2000) Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18(17):3093–3100. https://doi.org/10.1200/jco.2000.18.17.3093
doi: 10.1200/jco.2000.18.17.3093
pubmed: 10963637
Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19(14):3312–3322
doi: 10.1200/JCO.2001.19.14.3312
Rose PG, Maxson JH, Fusco N, Mossbruger K, Rodriguez M (2001) Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol 82(2):323–328. https://doi.org/10.1006/gyno.2001.6272
doi: 10.1006/gyno.2001.6272
pubmed: 11531287
Lorusso D, Naldini A, Testa A, D’Agostino G, Scambia G, Ferrandina G (2004) Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile? Oncology 67(3–4):243–249. https://doi.org/10.1159/000081324
doi: 10.1159/000081324
pubmed: 15557785
Wilailak S, Linasmita V (2004) A study of pegylated liposomal doxorubicin in platinum-refractory epithelial ovarian cancer. Oncology 67(3–4):183–186. https://doi.org/10.1159/000081315
doi: 10.1159/000081315
pubmed: 15557776
Chou HH, Wang KL, Chen CA, Wei LH, Lai CH, Hsieh CY, Yang YC, Twu NF, Chang TC, Yen MS (2006) Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up. Gynecol Oncol 101(3):423–428. https://doi.org/10.1016/j.ygyno.2005.10.027
doi: 10.1016/j.ygyno.2005.10.027
pubmed: 16325239
Mutch DG, Orlando M, Goss T, Teneriello MG, Gordon AN, McMeekin SD, Wang Y, Scribner DR Jr, Marciniack M, Naumann RW, Secord AA (2007) Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25(19):2811–2818. https://doi.org/10.1200/jco.2006.09.6735
doi: 10.1200/jco.2006.09.6735
pubmed: 17602086
Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, Del Medico P, Scaltriti L, Katsaros D, Priolo D, Scambia G (2008) Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 26(6):890–896. https://doi.org/10.1200/jco.2007.13.6606
doi: 10.1200/jco.2007.13.6606
pubmed: 18281662
Colombo N, Kutarska E, Dimopoulos M, Bae DS, Rzepka-Gorska I, Bidzinski M, Scambia G, Engelholm SA, Joly F, Weber D, El-Hashimy M, Li J, Souami F, Wing P, Engelholm S, Bamias A, Schwartz P (2012) Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol 30(31):3841–3847. https://doi.org/10.1200/jco.2011.38.8082
doi: 10.1200/jco.2011.38.8082
pubmed: 22987083
Blank N, Laskov I, Kessous R, Kogan L, Lau S, Sebag IA, Gotlieb WH, Rudski L (2017) Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin. Cancer Chemother Pharmacol 80(4):737–743. https://doi.org/10.1007/s00280-017-3412-8
doi: 10.1007/s00280-017-3412-8
pubmed: 28801766
Bollinger A, Pfister G, Hoffmann U, Franzeck UK (1989) Fluorescence microlymphography in chronic venous incompetence. Int Angiol 8(4 Suppl):23–26
pubmed: 2483727